Invega Hafyera

(paliperidone)
Company
Janssen
Product Web site
FDA Label

Indications

  • (08/30/2021)

    Treatment of schizophrenia in adults after they have been adequately treated with:
    • A once-a-month paliperidone palmitate extended-release injectable suspension (e.g., INVEGA SUSTENNA) for at least four months or
    • An every-three-month paliperidone palmitate extended-release injectable suspension (e.g., INVEGA TRINZA) for at least one three-month cycle.